1.1. Adults

Gabapentin (Neurontin®, Gralise®) is FDA-approved for use in adults with postherpetic neuralgia pain and as adjunctive therapy for managing partial seizures with or without secondary generalization in epileptic patients.1-6 Gabapentin enacarbil (Horizant®) has been FDA-approved for management of moderate-to-severe restless legs syndrome (RLS) in adults, and is also approved for pain reduction in postherpetic neuralgia (PHN).1-4, 7 Gralise® and Horizant® are not interchangeable with Neurontin® and available generics due to differing chemical forms and pharmacokinetic properties. Maximum recommended adult dosages are summarized in Table 1^1-7. The maximum time interval between gabapentin immediate-release doses should not exceed 12 hours. Patient profiles containing doses that exceed the maximum recommended dose will be reviewed^1-15.

While not FDA-approved, gabapentin has also been evaluated in adult clinical trials for use in neuropathic pain, fibromyalgia, and vasomotor symptoms with favorable results^1-3.